Candel Therapeutics Inc. has announced positive interim data from its ongoing phase 1b clinical trial evaluating CAN-3110 (linoserpaturev) in patients with recurrent glioblastoma. The company reported encouraging clinical benefit and evidence of immune activation in the tumor microenvironment following repeated administration of CAN-3110. These results have been published in the journal Science Translational Medicine. Candel Therapeutics plans to design a small phase 2 clinical trial of CAN-3110 in recurrent glioblastoma. The drug has previously received FDA Fast Track Designation and Orphan Drug Designation for the treatment of recurrent high-grade glioma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544677-en) on October 14, 2025, and is solely responsible for the information contained therein.